Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoni Ribas

Showing results (81-90 of 467) with videos related to

Pageof 47
Sort By:
Heart (British Cardiac Society)|March 16, 2021
Cardiotoxicities of novel cancer immunotherapiesAshley F Stein-Merlob, Michael V Rothberg, Antoni Ribas, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
Prioritization of SARS-CoV-2 epitopes using a pan-HLA and global population inference approachKatie M Campbell, Gabriela Steiner, Daniel K Wells, et al.
Cancer Discovery|April 13, 2021
Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19Mihaela Aldea, Jean-Marie Michot, Francois-Xavier Danlos, et al.
Oncoimmunology|September 14, 2016
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanomaBlanca Homet Moreno, Stephen Mok, Begonya Comin-Anduix, et al.
The Journal of Investigative Dermatology|October 15, 2010
siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomideJonathan E Zuckerman, Teli Hsueh, Richard C Koya, et al.
Anticancer Research|March 25, 2010
Immune rejection in a humanized model of murine prostate cancerDörthe Schaue, Richard C Koya, Yu-Pei Liao, et al.
Oncoimmunology|July 30, 2013
BRAF-targeted therapy and immune responses to melanomaShin Foong Ngiow, Deborah A Knight, Antoni Ribas, et al.
Immunotherapy|January 5, 2021
Acute interstitial nephritis and PR3-ANCA following reintroduction of pembrolizumab: a case reportMatthew Mulroy, Sanaz Ghafouri, Anthony Sisk, et al.
Nature Reviews. Drug Discovery|October 27, 2023
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteomeChristopher A Klebanoff, Smita S Chandran, Brian M Baker, et al.
Biotechniques|March 17, 2017
Preparation of peptide-MHC and T-cell receptor dextramers by biotinylated dextran dopingMichael T Bethune, Begoña Comin-Anduix, Yu-Hsien Hwang Fu, et al.
Pageof 47

Showing results (81-90 of 467) with videos related to

Sort By:
Pageof 47
Heart (British Cardiac Society)|March 16, 2021
Cardiotoxicities of novel cancer immunotherapiesAshley F Stein-Merlob, Michael V Rothberg, Antoni Ribas, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
Prioritization of SARS-CoV-2 epitopes using a pan-HLA and global population inference approachKatie M Campbell, Gabriela Steiner, Daniel K Wells, et al.
Cancer Discovery|April 13, 2021
Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19Mihaela Aldea, Jean-Marie Michot, Francois-Xavier Danlos, et al.
Oncoimmunology|September 14, 2016
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanomaBlanca Homet Moreno, Stephen Mok, Begonya Comin-Anduix, et al.
The Journal of Investigative Dermatology|October 15, 2010
siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomideJonathan E Zuckerman, Teli Hsueh, Richard C Koya, et al.
Anticancer Research|March 25, 2010
Immune rejection in a humanized model of murine prostate cancerDörthe Schaue, Richard C Koya, Yu-Pei Liao, et al.
Oncoimmunology|July 30, 2013
BRAF-targeted therapy and immune responses to melanomaShin Foong Ngiow, Deborah A Knight, Antoni Ribas, et al.
Immunotherapy|January 5, 2021
Acute interstitial nephritis and PR3-ANCA following reintroduction of pembrolizumab: a case reportMatthew Mulroy, Sanaz Ghafouri, Anthony Sisk, et al.
Nature Reviews. Drug Discovery|October 27, 2023
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteomeChristopher A Klebanoff, Smita S Chandran, Brian M Baker, et al.
Biotechniques|March 17, 2017
Preparation of peptide-MHC and T-cell receptor dextramers by biotinylated dextran dopingMichael T Bethune, Begoña Comin-Anduix, Yu-Hsien Hwang Fu, et al.
Pageof 47